- Home
- CCEC vs NVAX Comparison
CCEC vs NVAX Comparison
Compare CCEC & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEC
- NVAX
- Stock Information
- Founded
- CCEC 2007
- NVAX 1987
- Country
- CCEC Greece
- NVAX United States
- Employees
- CCEC N/A
- NVAX N/A
- Industry
- CCEC Marine Transportation
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CCEC Consumer Discretionary
- NVAX Health Care
- Exchange
- CCEC Nasdaq
- NVAX Nasdaq
- Market Cap
- CCEC 1.3B
- NVAX 1.4B
- IPO Year
- CCEC 2007
- NVAX 1995
- Fundamental
- Price
- CCEC $22.15
- NVAX $8.69
- Analyst Decision
- CCEC Buy
- NVAX Hold
- Analyst Count
- CCEC 1
- NVAX 6
- Target Price
- CCEC $26.00
- NVAX $11.33
- AVG Volume (30 Days)
- CCEC 12.2K
- NVAX 4.7M
- Earning Date
- CCEC 10-30-2025
- NVAX 11-11-2025
- Dividend Yield
- CCEC 5.42%
- NVAX N/A
- EPS Growth
- CCEC 62.73
- NVAX N/A
- EPS
- CCEC 4.04
- NVAX 2.54
- Revenue
- CCEC $424,701,000.00
- NVAX $1,078,718,000.00
- Revenue This Year
- CCEC $17.10
- NVAX $61.25
- Revenue Next Year
- CCEC $13.73
- NVAX N/A
- P/E Ratio
- CCEC $13.14
- NVAX $3.35
- Revenue Growth
- CCEC 84.28
- NVAX 9.22
- 52 Week Low
- CCEC $14.09
- NVAX $5.01
- 52 Week High
- CCEC $24.83
- NVAX $11.55
- Technical
- Relative Strength Index (RSI)
- CCEC 49.96
- NVAX 51.59
- Support Level
- CCEC $21.59
- NVAX $8.19
- Resistance Level
- CCEC $23.15
- NVAX $8.83
- Average True Range (ATR)
- CCEC 0.88
- NVAX 0.42
- MACD
- CCEC -0.01
- NVAX -0.05
- Stochastic Oscillator
- CCEC 46.23
- NVAX 42.41
About CCEC Capital Clean Energy Carriers Corp. Common Share
Capital Clean Energy Carriers Corp is an international shipping company. It is the platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.